Liminatus Pharma advances IBA101 CD47 inhibitor toward IND submissions in H2 2026

Liminatus Pharma, Inc.

• Completed GLP toxicology studies at Charles River; no clinically meaningful hemoglobin or platelet reductions in primates.
• Plans simultaneous IND submissions to FDA and Korea's MFDS in H2 2026; site activations and patient screening start early 2027.
• Partnered with Dr. Se-Hoon Lee at Samsung Medical Center for Phase 1 trial in NSCLC, including 3+3 dose-escalation and PD-1/PD-L1 combination arms.
• Preclinical combination data with PD-1/PD-L1 inhibitors showed increased complete response rates versus monotherapy.
• Engineered epitope selectivity and Fc modifications designed to avoid anemia/thrombocytopenia that halted earlier CD47 programs.